Compare GERN & DEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GERN | DEC |
|---|---|---|
| Founded | 1990 | 2001 |
| Country | United States | United States |
| Employees | 229 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2022 |
| Metric | GERN | DEC |
|---|---|---|
| Price | $1.55 | $17.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $2.17 | ★ $21.83 |
| AVG Volume (30 Days) | ★ 17.1M | 1.2M |
| Earning Date | 05-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 6.67% |
| EPS Growth | N/A | ★ 311.06 |
| EPS | N/A | ★ 4.58 |
| Revenue | N/A | ★ $1,829,142,000.00 |
| Revenue This Year | $26.91 | $18.28 |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | ★ N/A | $3.79 |
| Revenue Growth | N/A | ★ 141.54 |
| 52 Week Low | $1.04 | $10.08 |
| 52 Week High | $2.01 | $17.40 |
| Indicator | GERN | DEC |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 76.26 |
| Support Level | $1.24 | $14.04 |
| Resistance Level | $1.70 | N/A |
| Average True Range (ATR) | 0.10 | 0.57 |
| MACD | -0.01 | 0.30 |
| Stochastic Oscillator | 37.50 | 97.63 |
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Diversified Energy Co is an independent energy company focused on natural gas and liquids production, transportation, marketing and well retirement, located within the Appalachian and Central regions of the United States. Its principal focus is on enhancing producing wells, not drilling new wells, thereby allowing it to optimise PDP revenues and reduce costs. The company derives revenues from the sale of oil, natural gas and natural gas liquids.